Literature DB >> 8786293

Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes.

I F Ciernik1, J A Berzofsky, D P Carbone.   

Abstract

Delivery of genetic expression constructs into living animals can effectively induce both humoral and cellular immunity to the expressed proteins. Here we test the effectiveness of genetic immunization with a minigene coding for single epitopes derived from mutant p53 or from HIV gp120. We show that when these constructs are delivered by particle bombardment-mediated DNA transfer into the skin of mice, it results in efficient induction of tumor protective CTL. The immunogenicity of the epitope derived from mutant p53 is significantly enhanced if the epitope sequence is fused in frame with the adenovirus E3 leader sequence to target the epitope to the endoplasmic reticulum, thus acting like a "genetic adjuvant." We conclude that genetic T cell epitope immunization is an alternative to peptide-based techniques for eliciting an effective immune response targeted against a single defined epitope. in some cases, the fusion of the gene product of the DNA vaccine vector with an endoplasmic reticulum targeting sequence may enhance immune induction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8786293

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  Strategies for improving responses to DNA vaccines.

Authors:  J S Boyle; I G Barr; A M Lew
Journal:  Mol Med       Date:  1999-01       Impact factor: 6.354

2.  Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide.

Authors:  Deborah M Prinz; S Louise Smithson; Thomas Kieber-Emmons; M A Julie Westerink
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

3.  Induction of cell-mediated immunity against Mycobacterium tuberculosis using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein.

Authors:  D P Fonseca; B Benaissa-Trouw; M van Engelen; C A Kraaijeveld; H Snippe; A F Verheul
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 4.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Authors:  Shaw-Wei D Tsen; Augustine H Paik; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

5.  Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences.

Authors:  Z Li; A Howard; C Kelley; G Delogu; F Collins; S Morris
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

6.  The signal peptide sequence impacts the immune response elicited by a DNA epitope vaccine.

Authors:  Dimitrios Vatakis; Minnie McMillan
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

Review 7.  Genetic vaccines--a revolution in vaccinology?

Authors:  Z Q Xiang; S Pasquini; Z He; H Deng; Y Wang; M A Blaszczyk-Thurin; H C Ertl
Journal:  Springer Semin Immunopathol       Date:  1997

8.  DNA immunization with minigenes: low frequency of memory cytotoxic T lymphocytes and inefficient antiviral protection are rectified by ubiquitination.

Authors:  F Rodriguez; L L An; S Harkins; J Zhang; M Yokoyama; G Widera; J T Fuller; C Kincaid; I L Campbell; J L Whitton
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

Review 9.  Molecular biology of pseudorabies virus: impact on neurovirology and veterinary medicine.

Authors:  Lisa E Pomeranz; Ashley E Reynolds; Christoph J Hengartner
Journal:  Microbiol Mol Biol Rev       Date:  2005-09       Impact factor: 11.056

10.  NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.

Authors:  Sacha Gnjatic; Nasser K Altorki; Derek Ng Tang; Shi-Ming Tu; Vikas Kundra; Gerd Ritter; Lloyd J Old; Christopher J Logothetis; Padmanee Sharma
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.